Nanotube bottoms are uniformly etched to produce consistent nanoscale pores.

The Drug Adherence Challenge

"Drugs don't work in patients who don't take them"

~ C. Everett Koop

Pressure from payers for improved adherence is driving the need to innovate novel solutions in drug delivery; with only 61.4% of patients actually taking their medication, non-adherence costs the United States, alone, more than $100B annually. In addition to the pain and compliance issues associated with injections and infusions, the delivery profile is often non-optimal, negatively affecting treatment outcomes. Oral delivery via pills does not have the pain associated with injections and infusions, yet still suffers from poor adherence. Extended release implants address all of these issues head on, and likely improve patient outcomes.

Nano Precision Medical is developing a biocompatible, miniaturized, subdermal implant with the NanoPortalTM membrane to provide long-term, substantially constant-rate delivery of therapeutic macromolecules for up to a year.

Poor adherence is a significant health issue and associated with increased hospitalization and mortality1

Adherence reduces healthcare resource use and decreases healthcare cost2

Even weekly dosing of GLP-1s has low adherence3,4

Simpler treatment regimens improve patient satisfaction5, adherence1, QoL and clinical outcomes1,5

Adherence significantly improves treatment goals of HbA1C reduction6,7 and weight loss5, and non-adherence can account for the difference in outcomes between RCTs and RWE6

Adherence to diabetes meds is low1,8 and is associated with inadequate glycemic control, higher medical costs and higher mortality9

1Giorgino 2018
2Hamersky 2019
3Weiss 2020
4Mody 2020
5Patel 2019
6Carls 2017
7Buysman 2015
8Cai 2017
9Polonsky 2016

The American Diabetes Association (ADA) encourages treatment options that address adherence

ADA Standards of Care have adopted language to recognize the many hurdles leading to poor adherence and persistence. We would like to encourage the FDA to consider this unmet need when assessing new therapies for diabetes and to prioritize treatment options that:

Non-adherence has negative patient
and financial impacts

  • Reduced efficacy of treatments

  • Higher probability of hospitalizations, ED visits

  • Acute complications more likely to go undiagnosed

  • Increased acute care and hospitalization expenses for type 2 diabetes

  • Non-adherence results in avoidable expenses in the US of an estimated $105.4bn /yr

The NPM-119 implant can enable guaranteed adherence

  • Orals and injectables do not guarantee adherence, and thus patients do not receive maximum benefit

  • The NPM-119 implant can enable guaranteed adherence, and thus positive patient outcomes are maximized

There is a dual pharma and payer incentive to adopt technology that improves adherence

  • Pharmaceutical revenue increases by ~$5,500* per year per patient due to higher drug utilization

  • Healthcare providers incur savings per patient of ~$3,920 (acute care) and ~$1,507 (outpatient) per year* due to:

  • Fewer hospitalizations and ED visits

  • Reduced acute care costs and outpatient costs

  • Better patient outcomes